Image courtesy of Kaiser Permanente

The drug: Remicade
Company: Johnson & Johnson/Merck/Mitsubishi Tanabe Pharma
Estimated worldwide sales 2012: $7.67 billion

Johnson & Johnson ($JNJ) and Merck ($MRK) still share Remicade. But J&J now has the lion's share of the drug, thanks to a renegotiated marketing partnership. And that means J&J expects a bigger chunk of revenue from Remicade this year, while Merck is looking for less. All told, Remicade is expected to bring in $7.67 billion.

When Merck merged with J&J's original Remicade marketing partner, Schering-Plough, that triggered a dispute that finally wrapped up in April 2011. Merck agreed to pay J&J $500 million and concede some of its sales territories and profits. But it held onto territories that accounted for about 70% of its previous Remicade sales. And the two companies agreed to split profits 50-50, rather than the 58-42--in Merck's favor--previously arranged.

So far, Remicade sales have already dropped for Merck. The new partnership went into effect last July, and sales inched downward to $2.67 billion. For the first quarter of this year, however, Remicade dropped by 28%, Merck said.

Meanwhile, Remicade is J&J's biggest drug. Its sales for the first half of the year grew by 9.1% to $1.77 billion. And the company is rejigging its Remicade apparatus for the long haul. The company said it would move production of Remicade to Puerto Rico from a plant in Switzerland.

For more:
Janssen's Remicade attacks inflammation to beat depression
Merck's diabetes drugs offset Remicade sales decline
J&J brings arbitrators into Remicade dispute
Merck's Remicade face-off puts $2.7B at risk


Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.